SUTRO BIOPHARMA, INC.
Company Stats
- Market Cap
- $267.1M
- as of Sep 30, 2026
- Shares Outstanding
- 16.6M
- Free Float
- 60.7%
Income Statement
- Revenue
- $102.5M
- Operating Income
- -$158.4M
- Net Income
- -$191.1M
- EBITDA
- -$151.0M
- Non-cash Impairment
- $1.7M
- Revenue Growth, 3Y
- 14.8%
- FCF Margin, 3Y Avg
- -185.2%
- FCF Margin, Worst Year
- -309.8%
Cash Flow
- Free Cash Flow
- -$177.2M
- FCF Yield
- -66.4%
- Owner FCF Yield
- -71.6%
Balance Sheet
- Cash & Equivalents
- $58.1M
Returns & Capital
- SBC, 3Y Avg
- $21.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $102.5M | -$177.2M | -172.9% |
| FY2024 | $62.0M | -$192.2M | -309.8% |
| FY2023 | $153.7M | -$111.8M | -72.7% |
| FY2022 | $67.8M | $3.3M | 4.8% |
| FY2021 | $61.9M | -$82.0M | -132.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges